CMIC Group was founded in 1992 as the first contract research organization (CRO) in Japan. To enable pharmaceutical and biotech companies to develop better medicine sooner, the group expanded service solutions to contract development and manufacturing (CDMO), site management (SMO), and market solutions. CMIC also contributes to the broader healthcare market. Leveraging vast experiences and expertise in the medical industry, CMIC offers solutions using a new ecosystem of healthcare to support individuals and local governments. CMIC strives to be a Personal Health Value Creator (PHVC) to meet our global customers’ needs in the U.S., Japan, and broader Asia.
In addition to Japan, CMIC covers the broader Asia-Pacific region with strong clinical capabilities, including South Korea, Singapore, Taiwan, Hong Kong, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, Australia, and New Zealand as a CRO. CMIC offers Phases I–IV clinical development execution across a broad range of therapeutic areas, leveraging extensive expertise gained through the management of multinational clinical trials. CMIC group has been inspected and passed inspections from several international regulatory authorities: US FDA, Japan PMDA, Korea MFDS, Taiwan FDA and Singapore HSA.